Randomized, Double-Blind, Pacebo-Controlled, Phase 3 Trial of ZGN-440 (Subcutaneous Beloranib in Suspension) in Obese Subjects with Prader-Willi Syndrome to Evaluate Total Body Fat Mass, Food-related Behavior and Safety over 6 Months